These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 24943493)

  • 1. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
    Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
    Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.
    Lordick F
    Future Oncol; 2011 Feb; 7(2):187-99. PubMed ID: 21345138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Predictive diagnosis of HER2 in gastric adenocarcinoma].
    Daum O; Skálová A; Rozkos T; Laco J
    Cesk Patol; 2011 Oct; 47(4):160-3. PubMed ID: 22145214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
    Kaur A; Dasanu CA
    Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options.
    Koltz BR; Hicks DG; Whitney-Miller CL
    Biotech Histochem; 2012 Jan; 87(1):40-5. PubMed ID: 21745161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
    Bang YJ
    J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy for gastric cancer--current status.
    Kulig J; Kołodziejczyk P; Kulig P; Legutko J
    J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
    Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
    Gomez-Martin C; Plaza JC; Pazo-Cid R; Salud A; Pons F; Fonseca P; Leon A; Alsina M; Visa L; Rivera F; Galan MC; Del Valle E; Vilardell F; Iglesias M; Fernandez S; Landolfi S; Cuatrecasas M; Mayorga M; Jose Paulés M; Sanz-Moncasi P; Montagut C; Garralda E; Rojo F; Hidalgo M; Lopez-Rios F
    J Clin Oncol; 2013 Dec; 31(35):4445-52. PubMed ID: 24127447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 testing in gastric and gastroesophageal adenocarcinomas.
    Vakiani E
    Adv Anat Pathol; 2015 May; 22(3):194-201. PubMed ID: 25844677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
    Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
    Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
    Lorenzen S; Lordick F
    Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive response to trastuzumab in a case of HER2-overexpressing metastatic gastric cancer that presented as severe thrombocytopenia.
    Choi JH; Han HS; Lee HC; Lee OJ; Kim JT; Lim SN; Lee KH; Kim ST
    Onkologie; 2011; 34(11):621-4. PubMed ID: 22104159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge.
    Hicks DG; Whitney-Miller C
    Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):506-8. PubMed ID: 22089490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
    Hechtman JF; Polydorides AD
    Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 testing in gastric cancer.
    Albarello L; Pecciarini L; Doglioni C
    Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-positive gastric cancer with paraaortic nodal metastasis successfully resected after chemotherapy with trastuzumab: a case report.
    Ikari N; Nakajima G; Taniguchi K; Sasagawa T; Narumiya K; Yamada T; Kudo K; Kitamura Y; Hayashi K; Nishikawa T; Yamamoto M
    Anticancer Res; 2014 Feb; 34(2):867-72. PubMed ID: 24511024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of erythropoietin receptor with human epidermal growth factor 2 may counteract trastuzumab inhibition in gastric cancer.
    Li R; Yuan L; Wang J; Wang J
    Med Hypotheses; 2011 Dec; 77(6):948-52. PubMed ID: 21944379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer.
    Inui T; Asakawa A; Morita Y; Mizuno S; Natori T; Kawaguchi A; Murakami M; Hishikawa Y; Inui A
    J Intern Med; 2006 Nov; 260(5):484-7. PubMed ID: 17040255
    [No Abstract]   [Full Text] [Related]  

  • 20. HER2-positive gastric cancer.
    Boku N
    Gastric Cancer; 2014 Jan; 17(1):1-12. PubMed ID: 23563986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.